Naltrexone and Buprenorphine Market By Product Type (Buprenorphine, Naltrexone), By Formulation (Tablets, Capsules, Sublingual Films, Injectable), By Therapeutic Application (Opioid Dependence Treatment, Alcohol Dependence Treatment, Pain Management), By End User (Hospitals, Clinics, Rehabilitation Centres, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Dec 2024 | Report ID: MI1643 | 215 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Product Type

  • Buprenorphine
  • Naltrexone

By Formulation

  • Tablets
  • Capsules
  • Sublingual Films
  • Injectable

By Therapeutic Application

  • Opioid Dependence Treatment
  • Alcohol Dependence Treatment
  • Pain Management

By End User

  • Hospitals
  • Clinics
  • Rehabilitation Centres
  • Homecare Settings

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

List of Companies:

  • Indivior
  • Teva Pharmaceutical Industries
  • Mundipharma
  • Pfizer
  • Mallinckrodt Pharmaceuticals
  • Eli Lilly and Company
  • AbbVie
  • Amgen
  • Alkermes
  • Boehringer Ingelheim
  • Zydus Cadila
  • Sandoz
  • Mylan
  • Johnson & Johnson
  • Novartis
  • GSK (GlaxoSmithKline)
  • Cipla
  • Dr. Reddy’s Laboratories

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing